

Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021

<https://marketpublishers.com/r/A576EE933339EN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A576EE933339EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute Bacterial Skin and Skin Structure Infections Understanding

Acute Bacterial Skin and Skin Structure Infections: Overview

Acute Bacterial Skin and Skin Structure Infection is a bacterial infection of the skin and associated tissues. The FDA defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm², accompanied by lymph node enlargement or systemic symptoms such as fever $\geq 38^{\circ}\text{C}$ (100.4°F). Some of the most common bacterial pathogens that cause Acute Bacterial Skin and Skin Structure Infections are *Streptococcus pyogenes* and *Staphylococcus aureus*, including methicillin-resistant *S.aureus*. Less common causes include other

Streptococcus species, Enterococcus faecalis, or Gram Negative bacteria.

'Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Bacterial Skin and Skin Structure Infections pipeline landscape is provided which includes the disease overview and Acute Bacterial Skin and Skin Structure Infections treatment guidelines. The assessment part of the report embraces, in depth Acute Bacterial Skin and Skin Structure Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Bacterial Skin and Skin Structure Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Bacterial Skin and Skin Structure Infections R&D. The therapies under development are focused on novel approaches to treat/improve Acute Bacterial Skin and Skin Structure Infections.

Acute Bacterial Skin and Skin Structure Infections Emerging Drugs Chapters

This segment of the Acute Bacterial Skin and Skin Structure Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Bacterial Skin and Skin Structure Infections Emerging Drugs

Zevtera: Basilea Pharmaceutica

Zevtera (Ceftobiprole medocaril), the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes

methicillin-susceptible and resistant *Staphylococcus aureus* (MSSA, MRSA) and susceptible *Pseudomonas* spp. The drug is approved and marketed as Zevtera® and Mabelio® in a number of countries in Europe and beyond. Basilea has entered into license and distribution agreements for the brand in Europe, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) regions. The drug is currently in Phase III stage of clinical trial evaluation to treat Acute Bacterial Skin and Skin Structure Infections.

Contezolid acefosamil: MicuRx Pharmaceuticals

Contezolid is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE), while offering physicians and patients a new therapeutic option than currently available oxazolidinone agents. The development of contezolid in China has been designated as a “Significant New Drugs Development Special Project”, and contezolid has also been granted QIDP designation and Fast Track status by the US FDA.

Further product details are provided in the report.....

Acute Bacterial Skin and Skin Structure Infections: Therapeutic Assessment

This segment of the report provides insights about the different Acute Bacterial Skin and Skin Structure Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Bacterial Skin and Skin Structure Infections

There are approx. 15+ key companies which are developing the therapies for Acute Bacterial Skin and Skin Structure Infections. The companies which have their Acute Bacterial Skin and Skin Structure Infections drug candidates in the most advanced stage, i.e. phase III include, Basilea Pharmaceutica.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical

development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute Bacterial Skin and Skin Structure Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intradermal

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Bacterial Skin and Skin Structure Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Bacterial Skin and Skin Structure Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Bacterial Skin and Skin Structure Infections drugs.

Acute Bacterial Skin and Skin Structure Infections Report Insights

Acute Bacterial Skin and Skin Structure Infections Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Acute Bacterial Skin and Skin Structure Infections Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute Bacterial Skin and Skin Structure Infections drugs?

How many Acute Bacterial Skin and Skin Structure Infections drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Bacterial Skin and Skin Structure Infections?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Bacterial Skin and Skin Structure Infections therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute Bacterial Skin and Skin Structure Infections and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Basilea Pharmaceutica

MicuRx Pharmaceuticals

TenNor Therapeutics Limited

GlaxoSmithKline

Debiopharm Group

Innovation Pharmaceuticals, Inc.

Botanix pharmaceuticals

Taxis Pharmaceuticals

Key Products

Zevtera

Contezolid acefosamil

TNP-2092

GSK2140944

Debio 1452

Brilacidin

TXA709

Contents

Introduction

Executive Summary

Acute Bacterial Skin and Skin Structure Infections: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Zevtera: Basilea Pharmaceutica

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Brilacidin: Innovation Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

TXA709: Taxis Pharmaceuticals

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
Cannabidiol: Botanix pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
Comparative Analysis
Acute Bacterial Skin and Skin Structure Infections Key Companies
Acute Bacterial Skin and Skin Structure Infections Key Products
Acute Bacterial Skin and Skin Structure Infections- Unmet Needs
Acute Bacterial Skin and Skin Structure Infections- Market Drivers and Barriers
Acute Bacterial Skin and Skin Structure Infections- Future Perspectives and Conclusion
Acute Bacterial Skin and Skin Structure Infections Analyst Views
Acute Bacterial Skin and Skin Structure Infections Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Acute Bacterial Skin and Skin Structure Infections

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Acute Bacterial Skin and Skin Structure Infections

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A576EE933339EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A576EE933339EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970